Valsartan

Valsartan
(IUPAC) ime
	(S)-3-metil-2-(N- {[2'-(2H-1,2,3,4-tetrazol-5-il)bifenil-4-il]metil}pentanamido)butanoinska kiselina
Klinički podaci
Robne marke	Diovan
AHFS/Drugs.com	Monografija
MedlinePlus	a697015
Identifikatori
CAS broj	137862-53-4
ATC kod	C09CA03
PubChem	60846
DrugBank	DB00177
ChemSpider	54833
UNII	80M03YXJ7I
KEGG	D00400
ChEBI	CHEBI:9927
ChEMBL	CHEMBL1069
Hemijski podaci
Formula	C24H29N5O3
Mol. masa	435,519 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1 ; Key: ACWBQPMHZXGDFX-QFIPXVFZSA-N
Farmakokinetički podaci
Bioraspoloživost	25%
Vezivanje za proteine plazme	95%
Poluvreme eliminacije	6 sata
Izlučivanje	Renalno 30%, bilijarno 70%
Farmakoinformacioni podaci
Licenca	US FDA:link
Trudnoća	D(US)
Pravni status	℞-only (SAD)
Način primene	oralno

Valsartan (Angiotan, Diovan) je antagonist angiotenzin II receptora sa posebno jakim afinitetom za tip I (AT₁) angiotenzinskog receptora. Blokiranjem dejstva angiotenzina, valsartan proširuje krvne sudove i redukuje krvni pritisak.^[6] U SAD, valsartan je indiciran za tretman visokog krvnog pritiska, zatajenja srca (CHF), ili post-miokardijalne infarkcije (MI).^[7] Valsartan je više od 12 miliona puta propisan 2005. godine u Sjedinjenim Državama, a globalna prodaja je bila oko $6,1 milijarde 2010.^[8] Patenti za valsartan i valsartan/hidrohlorotiazid su istekli septembra 2012.^[9]^[10]

Reference[uredi | uredi kod]

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Marks JW (15. 2. 2007.). „Valsartan, Diovan”. MedicineNet. Pristupljeno 4. 3. 2010.
↑ „Diovan prescribing information”. Novartis.
↑ "Novartis Annual Report" Arhivirano 2014-06-11 na Wayback Machine-u. Novartis. 2010. Retrieved June 15, 2011.
↑ Philip Moeller (29. 4. 2011.). „Blockbuster Drugs That Will Go Generic Soon”. U.S.News & World Report.
↑ Eva Von Schaper (5. 8. 2011.). „Novartis's Jimenez Has Blockbuster Plans For Diovan After Patent Expires”. Bloomberg.

Spoljašnje veze[uredi | uredi kod]

	Portal Medicina
	Portal Hemija

Diovan official website Novartis
U.S. Valsartan National Library of Medicine: Drug Information Portal
Diovan Prescribing information Novartis
Diovan HCT Prescribing information Novartis

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[5] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[Marks2007-6] Marks JW (15. 2. 2007.). „Valsartan, Diovan”. MedicineNet. Pristupljeno 4. 3. 2010.

[7] „Diovan prescribing information”. Novartis.

[8] "Novartis Annual Report" Arhivirano 2014-06-11 na Wayback Machine-u. Novartis. 2010. Retrieved June 15, 2011.

[9] Philip Moeller (29. 4. 2011.). „Blockbuster Drugs That Will Go Generic Soon”. U.S.News & World Report.

[10] Eva Von Schaper (5. 8. 2011.). „Novartis's Jimenez Has Blockbuster Plans For Diovan After Patent Expires”. Bloomberg.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

Valsartan

Reference[uredi | uredi kod]

Spoljašnje veze[uredi | uredi kod]

Navigacija

Pretraga